echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Hengrui, Chia Tai Tianqing, and Fosun Pharma lead the IND application of Category 1 new drugs!

    Hengrui, Chia Tai Tianqing, and Fosun Pharma lead the IND application of Category 1 new drugs!

    • Last Update: 2022-02-16
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Before a new drug is finally launched, two administrative approvals are required: one is clinical research approval, which involves IND (Investigational New Drug) application; the other is the completion of clinical research registration and marketing (NDA application)


    The number of Category 1 new drug applications in the IND reflects the reserve of mature innovative drug projects on the company's R&D line


    0 1

    The number of applications has exploded, exceeding 1,000 for two consecutive years


    Looking back at the IND applications for Category 1 new drugs in recent years, it can be found that the number of applications has grown rapidly since 2015.



    In August 2015, the State Council issued the "Opinions on Reforming the Review and Approval System for Drugs and Medical Devices", proposing reform measures such as priority review, drug marketing authorization holders, project management, communication and expert advisory committees to encourage innovation


    In October 2017, the General Office of the Central Committee of the Communist Party of China and the General Office of the State Council issued the "Opinions on Deepening the Reform of the Review and Approval System and Encouraging the Innovation of Drugs and Medical Devices", which proposed to optimize the clinical trial approval process, accept overseas clinical trial data, and speed up the review of urgently needed drugs.


    On July 27, 2018, the State Food and Drug Administration issued the "Announcement on Adjusting the Review and Approval Procedures for Drug Clinical Trials", which clearly proposed a 60-day clinical review time limit, and the clinical review speed was shortened from an average of 16 months to 60 days


    After almost every major reform measure, the number of new Class 1 drugs applied for clinical applications will increase substantially once


      0 2

    The number of chemical drug declarations is the largest, and the proportion is decreasing

      


    0 3

    The number of biological drug declarations is 31 times in 7 years

      


      0 4

    The declaration of proprietary Chinese medicines broke the bureau, from 0 to 43

      


      0 5

    Domestic enterprises are mainly reporting, and the growth rate is accelerated

      


      0 6

    Anti-tumor and immunomodulatory agents account for nearly 70%

      


      0 7

    Rapid growth in the number of common names declared

      


      


       0 9

    These 10 domestic companies have the largest number of applications

      
      Judging from the category 1 new drugs declared for IND, Hengrui is a well-deserved innovation leader among domestic pharmaceutical companies
    .
    From 2014 to 2021, a total of 106 generic names of Hengrui Medicine and its subsidiaries have applied for IND, of which 41 will be in 2021 alone
    .

      
      Followed by Chia Tai Tianqing, Fosun Pharma, Dongguang Sunshine, Junshi Bio, Hansoh Pharmaceutical, Innovent Bio, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, CSPC, BeiGene,
    etc.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.